MedTrace Logo

Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

NCT00607399 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2008-07-24

No results posted yet for this study

Summary

SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.

Conditions

Interventions

DRUG

SGX523 Capsules

This is a dose escalation study

Sponsors & Collaborators

  • SGX Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Gordon, MD · Premier Onocology, Arizona

  • Ramesh Ramanathan, MD · Scottsdale Healthcare

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-01-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607399 on ClinicalTrials.gov